If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
== Conservative and radical replacements == Not all amino acid replacements have the same effect on function or structure of protein. The magnitude of this process may vary depending on how similar or dissimilar the replaced amino acids are, as well as on their position in the sequence or the structure. Similarity between amino acids can be calculated based on substitution matrices, physico-chemical distance, or simple properties such as amino acid size or charge (see also amino acid chemical properties). Usually amino acids are thus classified into two types:
The US remained officially neutral after Iraq's invasion of Iran in 1980, which became the Iran–Iraq War, although it provided resources, political support, and some "non-military" aircraft to Iraq. In March 1982, Iran began a successful counteroffensive (Operation Undeniable Victory), and the US increased its support for Iraq to prevent Iran from forcing a surrender. In a US bid to open full diplomatic relations with Iraq, the country was removed from the US list of State Sponsors of Terrorism. Ostensibly, this was because of improvement in the regime's record, although former US assistant defense secretary Noel Koch later stated: "No one had any doubts about [the Iraqis'] continued involvement in terrorism ... The real reason was to help them succeed in the war against Iran." With Iraq's newfound success in the war, and the Iranian rebuff of a peace offer in July, arms sales to Iraq reached a record spike in 1982. When Iraqi president Saddam Hussein expelled Abu Nidal to Syria at the US's request in November 1983, the Reagan administration sent Donald Rumsfeld to meet Saddam as a special envoy and to cultivate ties. By the time the ceasefire with Iran was signed in August 1988, Iraq was heavily debt-ridden and tensions within society were rising. Most of its debt was owed to Saudi Arabia and Kuwait. Iraq's debts to Kuwait amounted to $14 billion. Iraq pressured both nations to forgive the debts, but they refused. The Iraq–Kuwait border dispute involved Iraqi claims to Kuwaiti territory.
=== Mechanically interlocked molecular architectures === Mechanically interlocked molecular architectures consist of molecules that are linked only as a consequence of their topology. Some non-covalent interactions may exist between the different components (often those that were used in the construction of the system), but covalent bonds do not. Supramolecular chemistry, and template-directed synthesis in particular, is key to the efficient synthesis of the compounds. Examples of mechanically interlocked molecular architectures include catenanes, rotaxanes, molecular knots, molecular Borromean rings, 2D [c2]daisy chain polymer and ravels.
Sources: en.wikipedia.org
=== The 53Mn – 53Cr chronometer === The short-lived 53Mn-53Cr chronometer is based on the radioactive decay of 53Mn to 53Cr with a half-life of 3.80 ± 0.23 million years. Because manganese and chromium are moderately volatile elements, their fractionation in the cooling solar nebula makes this chronometer particularly suited for dating volatile element depletion events in early Solar System materials. The initial homogeneous distribution of 53Mn in the Solar System, a prerequisite for its use as a chronometer, was established in early studies of Solar System materials. Applied to meteorites, 53Mn-53Cr systematics have provided key insights into the origin of chondrite parent bodies and the volatile element depletion history of the early Earth. The volatile element depletion of proto-Earth was established no later than ~3 million years after the formation of calcium-aluminium-rich inclusions (CAIs), contemporaneous with the dissipation of the protoplanetary disk, while full planetary accretion was completed within ~70 million years.
==== Childhood ==== Thomas wrote a number of accounts of his childhood growing up in Swansea, and there are also accounts available by those who knew him as a young child. Thomas wrote several poems about his childhood and early teenage years, including "Once it was the colour of saying" and "The hunchback in the park", as well as short stories such as The Fight and A Child's Christmas in Wales. Thomas's four grandparents played no part in his childhood. For the first ten years or so of his life, Thomas's Swansea aunts and uncles helped with his upbringing. These were his mother's three siblings, Polly and Bob, who lived in the St Thomas district of Swansea and Theodosia, and her husband, the Rev. David Rees, in Newton, Swansea, where parishioners recall Thomas sometimes staying for a month or so at a time. All four aunts and uncles spoke Welsh and English. Thomas's childhood also featured regular summer trips to the Llansteffan peninsula, a Welsh-speaking part of Carmarthenshire. In the land between Llangain and Llansteffan, his mother's family, the Williamses and their close relatives, worked a dozen farms with over a thousand acres between them. The memory of Fernhill, a dilapidated 15-acre farm rented by his maternal aunt, Ann Jones, and her husband, Jim Jones, is evoked in the 1945 lyrical poem "Fern Hill", but is portrayed more accurately in his short story, The Peaches.
== Military campaigns in Syria and Jazira == Ubayd Allah fought for Marwan and his tribal allies against the Qaysi tribes led by al-Dahhak ibn Qays al-Fihri, the governor of Damascus, at the Battle of Marj Rahit in August 684. The Qays were routed and al-Dahhak killed. Ubayd Allah was put in command of Marwan's army which, during Marj Rahit, consisted of 6,000 men from a handful of loyalist tribes. According to Kennedy, Ubayd Allah "clearly intended to rebuild the Syrian army which had served Mu'awiya and Yazid I so well". In the aftermath of Marj Rahit, Ubayd Allah oversaw campaigns against rebel Qaysi tribes for Marwan and his son and successor Abd al-Malik (r. 685–705) in the Jazira. However, Marwan's forces were too little to assert Umayyad rule throughout the caliphate. Thus, Ubayd Allah expanded recruitment to include various Qaysi tribes. He placed Husayn ibn Numayr al-Sakuni of Kindah as his second-in-command, and Shurahbil ibn Dhi'l Kala' of Himyar, Adham ibn Muhriz of Bahila, Rabi'a ibn al-Mukhariq of Banu Ghani and Jabala ibn Abd Allah of Khath'am as deputy commanders. Other than Husayn ibn Numayr, all of the commanders were either Qaysi or had earlier supported al-Dahhak against Marwan. In January 685, as Ubayd Allah was in Manbij preparing for the Umayyad reconquest of Iraq, Husayn ibn Numayr defeated the pro-Alid Penitents at the Battle of Ayn al-Warda. Ubayd Allah had been promised by Marwan the governorship over all of the lands he could conquer from the Alids and Ibn al-Zubayr, and he may have been sanctioned to plunder Kufa.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.